RNAZ Transcode Therapeutics, Inc.
Price Chart
Executive Summary
TransCode Therapeutics filed an S-3 registration statement to register up to 15,955,543 shares of common stock for resale by selling stockholders, primarily DEFJ LLC (an affiliate of CK Life Sciences), Tungsten Advisors affiliates, and Unleash Immuno Oncolytics. The shares represent approximately 1,740% of the current 916,968 outstanding shares, creating massive potential dilution. The company will not receive any proceeds from these sales. Conversion of the underlying preferred stock is contingent on stockholder approval, which has not yet been obtained.
Actionable Insight
The massive overhang of registered shares (17x current float) will likely pressure RNAZ stock significantly. Monitor for stockholder vote on preferred conversion — if approved, selling pressure could be immediate and severe. The going concern qualification and need for capital suggest this registration is a precursor to further dilution, not a routine filing.
Key Facts
- S-3 registers up to 15,955,543 shares for resale, representing ~1,740% of the 916,968 shares outstanding as of April 29, 2026
- Company receives no proceeds from any sales by selling stockholders
- Shares include 14,134,481 from DEFJ/ CK Life Sciences (84.2% pro forma ownership), 684,698 from Tungsten affiliates, and 1,136,364 from Unleash
- Conversion of Series A, B, and C Preferred Stock into common stock requires stockholder approval, which has not yet been obtained
- If stockholder approval is not received by December 31, 2026, DEFJ can require repurchase of Series A and B Preferred Stock at initial investment price
- Auditor's report includes a going concern explanatory paragraph
- Market cap is approximately $8M; the registered shares have a maximum aggregate offering price of ~$134.5M based on the filing fee calculation
Financial Impact
Potential dilution of up to 1,740% of current outstanding shares; maximum aggregate offering value of approximately $134.5 million based on $8.43 reference price
Risk Factors
- Extreme dilution risk — registered shares represent 1,740% of current outstanding shares
- Going concern qualification in auditor's report indicates potential inability to continue operations without additional financing
- Stockholder approval for preferred conversion is uncertain; failure could trigger repurchase obligations
- Nasdaq minimum bid price compliance risk given low market cap and potential selling pressure
Market Snapshot
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001104659-26-053187 |
| Document: tm2612989d1_ex-filingfees.htm | 0001104659-26-053187 |
| Document: tm2612989d1_ex5-1.htm | 0001104659-26-053187 |
| Document: tm2612989d1_23-1.htm | 0001104659-26-053187 |
| Document: tm2612989d1_23-2.htm | 0001104659-26-053187 |
| Document: 0001104659-26-053187-index-headers.html | 0001104659-26-053187 |
| Document: 0001104659-26-053187-index.html | 0001104659-26-053187 |
| Document: 0001104659-26-053187.txt | 0001104659-26-053187 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Apr 30, 2026
20d ago
|
S-3
| — | awaiting T+20 | — | — |
|
Apr 7, 2026
6w ago
|
8-K
| $8.70 $7.74 | ▲ +11.03% | ▲ +20.82% | $6.11 (+29.77%) |
|
Mar 3, 2026
11w ago
|
DEFA14A
| $9.84 $8.69 | ▼ −11.69% | ▼ −7.27% | $6.11 (−37.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access